SSI(SZ:002742)2022-12-06 23:40Group 1: Mergers and Acquisitions - The company has completed the acquisition of LiaoYuan BaiKang Pharmaceutical and is currently restructuring and merging with ChunRui Medical [2][3] - The company emphasizes the stability of the original management team of the acquired entities, retaining key personnel while integrating new members to enhance management [3] - Both BaiKang Pharmaceutical and ChunRui Medical are 100% wholly acquired, chosen over a controlling stake due to their historical background and dispersed shareholding structure [4] Group 2: Strategic Focus and Development - The company's short-term focus is on effectively integrating the acquired companies to lay a solid foundation for diversification and development in the pharmaceutical sector [4] - The chairman, with a military background, prioritizes industrial development and aims to enhance the company's profitability and intrinsic value through practical operations [4][5] - The company is committed to building a research and development platform and integrating the pharmaceutical industry chain to create a manufacturing base for specialty intermediates and active pharmaceutical ingredients [3] Group 3: Financial and Regulatory Aspects - The company has received feedback from the China Securities Regulatory Commission regarding its restructuring and fundraising plans, and will respond accordingly [5] - Some executives have reduced their holdings due to personal financial needs and the accumulation of funds, with the reduction being a legal right of shareholders [6] - The company plans to allocate funds raised from the public offering based on the pricing mechanism and subscription quotes after obtaining regulatory approval [6]